SIFCO INDUSTRIES INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that SIFCO INDUSTRIES INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Sep 30, 2018 | $111.21M | Dec 6, 2018 |
| FY2018 | Sep 30, 2017 | $121.46M | Dec 6, 2018 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $84.82M | Dec 22, 2025 |
| FY2024 | Sep 30, 2024 | $21.66M | Dec 26, 2024 |
| FY2024 | Jun 30, 2024 | $21.99M | Dec 26, 2024 |
| FY2024 | Mar 31, 2024 | $20.51M | Dec 26, 2024 |
| FY2024 | Dec 31, 2023 | $15.47M | Dec 26, 2024 |
| FY2024 | Sep 30, 2023 | $19.03M | Dec 26, 2024 |
| FY2024 | Jun 30, 2023 | $15.39M | Dec 26, 2024 |
| FY2024 | Mar 31, 2023 | $14.35M | Dec 26, 2024 |
| FY2024 | Dec 31, 2022 | $17.29M | Dec 26, 2024 |
| FY2023 | Sep 30, 2022 | $83.90M | Jan 2, 2024 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Sep 30, 2017 | $121.46M | Dec 20, 2017 |
| FY2017 | Sep 30, 2016 | $119.12M | Dec 20, 2017 |
| FY2015 | Sep 30, 2015 | $35.89M | Jan 29, 2016 |
| FY2015 | Jun 30, 2015 | $28.72M | Jan 29, 2016 |
| FY2015 | Mar 31, 2015 | $24.62M | Jan 29, 2016 |
| FY2015 | Dec 31, 2014 | $20.08M | Jan 29, 2016 |
| FY2015 | Sep 30, 2014 | $32.96M | Jan 29, 2016 |
| FY2015 | Jun 30, 2014 | $31.00M | Jan 29, 2016 |
| FY2015 | Mar 31, 2014 | $29.04M | Jan 29, 2016 |
| FY2015 | Dec 31, 2013 | $26.65M | Jan 29, 2016 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $10.59M | Dec 22, 2025 |
| FY2024 | Sep 30, 2024 | $2.32M | Dec 26, 2024 |
| FY2024 | Jun 30, 2024 | $2.71M | Dec 26, 2024 |
| FY2024 | Mar 31, 2024 | $1.49M | Dec 26, 2024 |
| FY2024 | Dec 31, 2023 | ($545.0K) | Dec 26, 2024 |
| FY2024 | Sep 30, 2023 | $163.0K | Dec 26, 2024 |
| FY2024 | Jun 30, 2023 | $2.21M | Dec 26, 2024 |
| FY2024 | Mar 31, 2023 | $587.0K | Dec 26, 2024 |
| FY2024 | Dec 31, 2022 | $385.0K | Dec 26, 2024 |
| FY2023 | Sep 30, 2022 | ($1.86M) | Jan 2, 2024 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($729.0K) | Dec 22, 2025 |
| FY2024 | Sep 30, 2024 | ($443.0K) | Dec 26, 2024 |
| FY2024 | Jun 30, 2024 | $72.0K | Dec 26, 2024 |
| FY2024 | Mar 31, 2024 | ($1.59M) | Dec 26, 2024 |
| FY2024 | Dec 31, 2023 | ($3.42M) | Dec 26, 2024 |
| FY2024 | Sep 30, 2023 | ($3.10M) | Dec 26, 2024 |
| FY2024 | Jun 30, 2023 | ($634.0K) | Dec 26, 2024 |
| FY2024 | Mar 31, 2023 | ($2.37M) | Dec 26, 2024 |
| FY2024 | Dec 31, 2022 | ($2.59M) | Dec 26, 2024 |
| FY2023 | Sep 30, 2022 | ($9.64M) | Jan 2, 2024 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $180.0K | Dec 22, 2025 |
| FY2025 | Sep 30, 2024 | ($5.15M) | Dec 22, 2025 |
| FY2024 | Sep 30, 2023 | ($9.00M) | Dec 26, 2024 |
| FY2023 | Sep 30, 2022 | ($14.07M) | Jan 2, 2024 |
| FY2022 | Sep 30, 2021 | ($1.10M) | Dec 23, 2022 |
| FY2021 | Sep 30, 2020 | $10.14M | Dec 10, 2021 |
| FY2020 | Sep 30, 2019 | ($7.04M) | Dec 23, 2020 |
| FY2019 | Sep 30, 2018 | ($5.91M) | Dec 16, 2019 |
| FY2018 | Sep 30, 2017 | ($11.53M) | Dec 6, 2018 |
| FY2017 | Sep 30, 2016 | ($12.07M) | Dec 20, 2017 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $0 | Dec 22, 2025 |
| FY2025 | Sep 30, 2024 | $0 | Dec 22, 2025 |
| FY2019 | Sep 30, 2019 | $0 | Dec 16, 2019 |
| FY2019 | Sep 30, 2018 | $0 | Dec 16, 2019 |
| FY2018 | Sep 30, 2017 | $0 | Dec 6, 2018 |
| FY2017 | Sep 30, 2016 | $0 | Dec 20, 2017 |
| FY2016 | Sep 30, 2015 | $0 | Dec 6, 2016 |
| FY2012 | Sep 30, 2012 | $1.05M | Nov 30, 2012 |
| FY2012 | Sep 30, 2011 | $946.0K | Nov 30, 2012 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $10.40M | Dec 22, 2025 |
| FY2025 | Sep 30, 2024 | $11.13M | Dec 22, 2025 |
| FY2024 | Sep 30, 2023 | $12.28M | Dec 26, 2024 |
| FY2023 | Sep 30, 2022 | $11.91M | Jan 2, 2024 |
| FY2022 | Sep 30, 2021 | $13.48M | Dec 23, 2022 |
| FY2021 | Sep 30, 2020 | $14.02M | Dec 10, 2021 |
| FY2020 | Sep 30, 2019 | $15.27M | Dec 23, 2020 |
| FY2019 | Sep 30, 2018 | $15.22M | Dec 16, 2019 |
| FY2018 | Sep 30, 2017 | $17.77M | Dec 6, 2018 |
| FY2017 | Sep 30, 2016 | $17.36M | Dec 20, 2017 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Sep 30, 2023 | ($1.36M) | Jan 2, 2024 |
| FY2023 | Sep 30, 2022 | $298.0K | Jan 2, 2024 |
| FY2022 | Sep 30, 2021 | $3.89M | Dec 23, 2022 |
| FY2021 | Sep 30, 2020 | $449.0K | Dec 10, 2021 |
| FY2020 | Sep 30, 2019 | $5.73M | Dec 23, 2020 |
| FY2019 | Sep 30, 2018 | $1.30M | Dec 16, 2019 |
| FY2018 | Sep 30, 2017 | $12.00M | Dec 6, 2018 |
| FY2017 | Sep 30, 2016 | $12.28M | Dec 20, 2017 |
| FY2012 | Sep 30, 2012 | $9.77M | Nov 30, 2012 |
| FY2012 | Sep 30, 2011 | $10.22M | Nov 30, 2012 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $73.39M | Dec 22, 2025 |
| FY2025 | Sep 30, 2024 | $104.62M | Dec 22, 2025 |
| FY2024 | Sep 30, 2023 | $96.28M | Dec 26, 2024 |
| FY2023 | Sep 30, 2022 | $97.27M | Jan 2, 2024 |
| FY2022 | Sep 30, 2021 | $110.67M | Dec 23, 2022 |
| FY2021 | Sep 30, 2020 | $121.95M | Dec 10, 2021 |
| FY2020 | Sep 30, 2019 | $96.10M | Dec 23, 2020 |
| FY2019 | Sep 30, 2018 | $102.24M | Dec 16, 2019 |
| FY2018 | Sep 30, 2017 | $110.89M | Dec 6, 2018 |
| FY2017 | Sep 30, 2016 | $130.46M | Dec 20, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $36.89M | Dec 22, 2025 |
| FY2025 | Sep 30, 2024 | $30.43M | Dec 22, 2025 |
| FY2025 | Sep 30, 2023 | $34.34M | Dec 22, 2025 |
| FY2024 | Sep 30, 2022 | $40.69M | Dec 26, 2024 |
| FY2023 | Sep 30, 2021 | $49.62M | Jan 2, 2024 |
| FY2022 | Sep 30, 2020 | $45.52M | Dec 23, 2022 |
| FY2021 | Sep 30, 2019 | $36.05M | Dec 10, 2021 |
| FY2020 | Sep 30, 2018 | $44.19M | Dec 23, 2020 |
| FY2019 | Sep 30, 2017 | $50.13M | Dec 16, 2019 |
| FY2018 | Sep 30, 2016 | $60.37M | Dec 6, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $3.49M | Dec 22, 2025 |
| FY2025 | Sep 30, 2024 | $3.49M | Dec 22, 2025 |
| FY2024 | Sep 30, 2023 | $3.49M | Dec 26, 2024 |
| FY2023 | Sep 30, 2022 | $3.49M | Jan 2, 2024 |
| FY2023 | Sep 30, 2021 | $3.49M | Jan 2, 2024 |
| FY2022 | Sep 30, 2020 | $3.49M | Dec 23, 2022 |
| FY2021 | Sep 30, 2019 | $3.49M | Dec 10, 2021 |
| FY2020 | Sep 30, 2018 | $12.02M | Dec 23, 2020 |
| FY2019 | Sep 30, 2017 | $12.17M | Dec 16, 2019 |
| FY2018 | Sep 30, 2016 | $11.75M | Dec 6, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $17.15M | Dec 22, 2025 |
| FY2025 | Sep 30, 2024 | $17.88M | Dec 22, 2025 |
| FY2024 | Sep 30, 2023 | $23.26M | Dec 26, 2024 |
| FY2023 | Sep 30, 2022 | $31.96M | Jan 2, 2024 |
| FY2022 | Sep 30, 2021 | $41.60M | Dec 23, 2022 |
| FY2021 | Sep 30, 2020 | $42.34M | Dec 10, 2021 |
| FY2020 | Sep 30, 2019 | $33.15M | Dec 23, 2020 |
| FY2019 | Oct 1, 2018 | $40.70M | Dec 16, 2019 |
| FY2019 | Sep 30, 2018 | $37.10M | Dec 16, 2019 |
| FY2018 | Sep 30, 2017 | $44.27M | Dec 6, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $491.0K | Dec 22, 2025 |
| FY2025 | Sep 30, 2024 | $1.71M | Dec 22, 2025 |
| FY2024 | Sep 30, 2023 | $21.0K | Dec 26, 2024 |
| FY2023 | Sep 30, 2022 | $1.17M | Jan 2, 2024 |
| FY2022 | Sep 30, 2021 | $346.0K | Dec 23, 2022 |
| FY2021 | Sep 30, 2020 | $427.0K | Dec 10, 2021 |
| FY2020 | Sep 30, 2019 | $341.0K | Dec 23, 2020 |
| FY2019 | Sep 30, 2018 | $1.25M | Dec 16, 2019 |
| FY2018 | Sep 30, 2017 | $1.40M | Dec 6, 2018 |
| FY2018 | Sep 30, 2016 | $471.0K | Dec 6, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Sep 30, 2018 | $3.55M | Dec 6, 2018 |
| FY2017 | Sep 30, 2017 | $7.94M | Dec 20, 2017 |
| FY2016 | Sep 30, 2016 | $34.87M | Dec 6, 2016 |
| FY2015 | Sep 30, 2015 | $43.81M | Jan 29, 2016 |
| FY2014 | Sep 30, 2014 | $8.43M | Dec 2, 2014 |
| FY2014 | Sep 30, 2013 | $7.38M | Dec 2, 2014 |
| FY2013 | Sep 30, 2012 | $19.68M | Nov 27, 2013 |
| FY2012 | Sep 30, 2011 | $1.19M | Nov 30, 2012 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 0 | Dec 22, 2025 |
| FY2024 | Sep 30, 2024 | 0 | Dec 26, 2024 |
| FY2024 | Jun 30, 2024 | 0 | Dec 26, 2024 |
| FY2024 | Mar 31, 2024 | 0 | Dec 26, 2024 |
| FY2024 | Dec 31, 2023 | 0 | Dec 26, 2024 |
| FY2024 | Sep 30, 2023 | 0 | Dec 26, 2024 |
| FY2024 | Jun 30, 2023 | 0 | Dec 26, 2024 |
| FY2024 | Mar 31, 2023 | 0 | Dec 26, 2024 |
| FY2024 | Dec 31, 2022 | 0 | Dec 26, 2024 |
| FY2023 | Sep 30, 2022 | (1) | Jan 2, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 0 | Dec 22, 2025 |
| FY2024 | Sep 30, 2024 | 0 | Dec 26, 2024 |
| FY2024 | Jun 30, 2024 | 0 | Dec 26, 2024 |
| FY2024 | Mar 31, 2024 | 0 | Dec 26, 2024 |
| FY2024 | Dec 31, 2023 | 0 | Dec 26, 2024 |
| FY2024 | Sep 30, 2023 | 0 | Dec 26, 2024 |
| FY2024 | Jun 30, 2023 | 0 | Dec 26, 2024 |
| FY2024 | Mar 31, 2023 | 0 | Dec 26, 2024 |
| FY2024 | Dec 31, 2022 | 0 | Dec 26, 2024 |
| FY2023 | Sep 30, 2022 | (1) | Jan 2, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 6.18M | Dec 22, 2025 |
| FY2025 | Sep 30, 2024 | 6.16M | Dec 22, 2025 |
| FY2024 | Sep 30, 2023 | 6.11M | Dec 26, 2024 |
| FY2023 | Sep 30, 2022 | 6.04M | Jan 2, 2024 |
| FY2022 | Sep 30, 2021 | 5.99M | Dec 23, 2022 |
| FY2021 | Sep 30, 2020 | 5.92M | Dec 10, 2021 |
| FY2020 | Sep 30, 2019 | 5.78M | Dec 23, 2020 |
| FY2019 | Sep 30, 2018 | 5.69M | Dec 16, 2019 |
| FY2018 | Sep 30, 2017 | 5.60M | Dec 6, 2018 |
| FY2017 | Sep 30, 2016 | 5.53M | Dec 20, 2017 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Sep 30, 2016 | $0 | Dec 6, 2016 |
| FY2015 | Sep 30, 2015 | $1.09M | Jan 29, 2016 |
| FY2014 | Sep 30, 2014 | $1.08M | Dec 2, 2014 |
| FY2013 | Sep 30, 2013 | $1.07M | Nov 27, 2013 |
| FY2013 | Sep 30, 2012 | $1.06M | Nov 27, 2013 |
| FY2011 | Sep 30, 2011 | $789.0K | Dec 1, 2011 |
| FY2011 | Sep 30, 2010 | $529.0K | Dec 1, 2011 |